Utilization of High-Frequency Irreversible Electroporation (H-FIRE) to modulate the tumor microenvironment and promote systemic immune system activation in breast cancer

Irving C. Allen,Veronica Ringel-Scaia,Sheryl Coutermarsh-Ott,Rebecca Brock,Melvin Lorenzo,Natalie White,Kenneth J. Oestreich,Scott Verbridge,Rafael Davalos

DOI: https://doi.org/10.4049/jimmunol.200.supp.178.9

2018-05-01

The Journal of Immunology

Abstract:Abstract Breast cancer is the most common malignancy among women, where almost 1.7 million new patients worldwide are diagnosed annually. Despite promising treatments for breast cancer, metastatic disease and recurrence remain significant challenges. There is no highly effective cure currently available once metastatic disease has developed. Thus, new therapeutic paradigms and treatment strategies are direly needed. High Frequency Irreversible Electroporation (H-FIRE) is a particularly novel and emerging therapeutic approach for tumor ablation. This technique uses a series of high-frequency, bipolar electric pulses applied through electrodes inserted directly into the targeted tumor to induce cancer cell death. Our overarching hypothesis predicts that local treatment of the breast tumor with H-FIRE will significantly stimulate the innate and adaptive immune system, resulting in improved survival outcomes. To test this hypothesis, we utilized a mouse 4T1 mammary tumor model. Here, we show that H-FIRE treatment of the primary tumor results in near complete ablation and a shift in the local tumor microenvironment from immunosuppressive to pro-inflammatory. This shift results in the recruitment of increased numbers of antigen presenting cells and T lymphocytes. Local H-FIRE treatment also significantly reduces 4T1 metastases in animals with an intact immune system, indicating increased engagement of a systemic anti-tumor immune response and improved activation of the adaptive immune system. We anticipate that this novel tumor ablation technology will improve conventional treatment strategies and complement emerging immunomodulatory approaches targeting primary tumors, metastatic lesions, and preventing recurrence.

immunology